A promising new diabetes drug may significantly change the way type 2 diabetes is treated, offering substantial improvements in both blood sugar control and weight loss, according to findings from a major phase 3 clinical trial presented at the American Diabetes Association (ADA) Scientific Sessions and published in The Lancet.

The drug, retatrutide, is a next-generation triple hormone receptor agonist currently being developed by Eli Lilly. Researchers found that adults with type 2 diabetes whose condition was not adequately controlled through diet and exercise alone experienced marked reductions in blood glucose levels and body weight after receiving the medication.

The 40-week study, led by Dr. Harpreet S. Bajaj, involved 537 adults with type 2 diabetes. Participants were randomly assigned to receive weekly injections of retatrutide at doses of 4 mg, 9 mg, or 12 mg, or a placebo.

By the end of the trial, patients receiving retatrutide showed significantly greater improvements in hemoglobin A1c—a key measure of long-term blood sugar control—compared with those receiving placebo.

Researchers reported average reductions in HbA1c of 1.69%, 1.86%, and 1.94% among patients receiving the 4 mg, 9 mg, and 12 mg doses, respectively. In comparison, participants in the placebo group experienced a reduction of 0.81%.

The drug's impact on body weight was equally impressive.

Patients receiving retatrutide lost between 11.5% and 15.3% of their body weight over the 40-week study period, depending on the dose administered. By contrast, participants receiving placebo lost an average of only 2.6% of their body weight.

The highest dose of retatrutide resulted in an average weight reduction exceeding 15%, a level of weight loss that researchers say could have important implications for slowing disease progression and improving overall metabolic health.

“The magnitude of weight loss observed with retatrutide has the potential to slow disease progression and reshape how we treat and manage type 2 diabetes,” Dr. Bajaj said.

Retatrutide belongs to a new class of medicines that simultaneously target three different hormone receptors involved in regulating blood sugar, appetite and energy balance. This triple-action mechanism is believed to contribute to its powerful effects on both glucose control and weight reduction.

The safety profile observed during the study was generally consistent with other medications in this category. The most commonly reported side effects were gastrointestinal symptoms such as nausea, vomiting and diarrhea. Researchers noted that these adverse effects were mostly mild to moderate in severity and tended to decrease over time as treatment continued.

Experts say the findings are particularly significant because excess body weight is one of the major drivers of type 2 diabetes progression and complications. Achieving substantial weight loss alongside improved glycemic control could help reduce the risk of cardiovascular disease, kidney disease and other diabetes-related health problems.

With the global burden of type 2 diabetes continuing to rise, the development of therapies capable of addressing both obesity and diabetes simultaneously has become a major focus of medical research.

While the results are highly encouraging, researchers caution that further evaluation and regulatory review are needed before retatrutide becomes widely available. The study was funded by Eli Lilly, and several investigators disclosed relationships with pharmaceutical companies, including the drug's developer.

Nevertheless, the trial adds to growing evidence that next-generation incretin-based therapies may redefine diabetes treatment by targeting both blood sugar levels and the underlying metabolic factors that drive the disease.

If future studies continue to confirm its benefits, retatrutide could emerge as one of the most powerful treatment options yet for people living with type 2 diabetes and obesity.